Stockscreener 앱 받기
1.63
2.40%
-0.04
시간 외 거래:
1.67
0.04
+2.45%
전일 마감가:
$1.67
열려 있는:
$1.7
하루 거래량:
1.15M
Relative Volume:
1.25
시가총액:
$147.23M
수익:
$70.14M
순이익/손실:
$-76.24M
주가수익비율:
-1.4685
EPS:
-1.11
순현금흐름:
$-57.06M
1주 성능:
-15.10%
1개월 성능:
-0.91%
6개월 성능:
-26.91%
1년 성능:
-70.52%
1일 변동 폭
$1.62
$1.70
1주일 범위
$1.62
$1.95
52주 변동 폭
$1.52
$6.0093
Codexis Inc Stock (CDXS) Company Profile
명칭
Codexis Inc
전화
650-421-8100
주소
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
CDXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.63 | 150.84M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-29 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-07 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-08-07 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2021-04-12 | 개시 | Piper Sandler | Overweight |
| 2021-03-01 | 개시 | Stifel | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-10 | 개시 | The Benchmark Company | Buy |
| 2019-01-17 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 개시 | Stephens | Overweight |
| 2017-10-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-31 | 개시 | Jefferies | Buy |
| 2017-01-26 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 개시 | H.C. Wainwright | Buy |
모두보기
Codexis Inc 주식(CDXS)의 최신 뉴스
Opaleye management sells Codexis (CDXS) shares worth $877,846 By Investing.com - Investing.com South Africa
Opaleye management sells Codexis (CDXS) shares for $1.87 million By Investing.com - Investing.com Australia
Opaleye management sells Codexis (CDXS) shares worth $877,846 - Investing.com
Codexis : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
MACD Signal: Why Codexis Inc stock could see breakout soonJuly 2025 Trade Ideas & AI Enhanced Trading Alerts - moha.gov.vn
Specialty Enzymes Market size to cross $12.2 Billion by 2035 | - openPR.com
Perhaps timely catching Codexis Inc (CDXS) would be a good idea - Setenews
Is Codexis Inc. stock supported by strong fundamentalsTrade Risk Report & Verified Technical Signals - Newser
Will Codexis Inc. stock benefit from upcoming earnings reportsMarket Risk Summary & Entry Point Confirmation Alerts - Newser
Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics - CBS News
Opaleye Management Inc. Reduces Stake in Codexis Inc. - GuruFocus
Enzyme Engineering Market is Going to Boom: Strategic Insights - openPR.com
A Look at Codexis Inc (CDXS) Shares in the Recent Past Indicates Growth - setenews.com
Major Shareholder Sells Off a Chunk of Codexis Stock! - TipRanks
Codexis (CDXS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Operating cash flow per share of Codexis, Inc. – DUS:4QK - TradingView
Owner Opaleye Management Inc Sells 514,341 ($877.8K) Of Codexis Inc [CDXS] - TradingView
Trading Recap: Is Codexis Inc. stock vulnerable to regulatory risksJuly 2025 Snapshot & Weekly Setup with High ROI Potential - BỘ NỘI VỤ
[Form 4] CODEXIS, INC. Insider Trading Activity - Stock Titan
Check out these key findings about Codexis Inc (CDXS) - setenews.com
Codexis Inc (CDXS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Telemark Asset Management LLC Increases Stock Position in Codexis, Inc. $CDXS - MarketBeat
Dir Wolf Files To Sell 8,952 Of Codexis Inc [CDXS] - TradingView
Can Codexis Inc. stock beat market expectations this quarter2025 Macro Impact & Weekly Watchlist for Consistent Profits - newser.com
Codexis strengthens board with biotech veteran Arthur Levin - MSN
Is Codexis Inc. stock attractive for ETFsTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Will Codexis Inc. stock outperform tech sector in 2025Quarterly Profit Report & Risk Managed Investment Entry Signals - newser.com
Will Codexis Inc. stock sustain high P E ratiosJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Why Codexis Inc. stock is considered a top pickJuly 2025 Summary & Risk Controlled Daily Plans - newser.com
Strategies to average down on Codexis Inc.July 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
Is Codexis Inc. stock dividend yield sustainableJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
How to escape a deep drawdown in Codexis Inc.July 2025 News Drivers & Risk Managed Investment Strategies - newser.com
Will Codexis Inc. stock deliver long term returnsJuly 2025 Sector Moves & Reliable Entry Point Alerts - newser.com
An analyst sees good growth prospects for Codexis Inc (CDXS) - Setenews
Will Codexis Inc. price bounce be sustainableJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Jeff Bluestone to step down as CEO of Sonoma BiotherapeuticsSan Francisco Business Times - The Business Journals
Sonoma Biotherapeutics Names Stephen Dilly as CEO - Contract Pharma
Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer - Business Wire
Can volume confirm reversal in Codexis Inc.Weekly Trade Analysis & Proven Capital Preservation Tips - newser.com
What risks investors should watch in Codexis Inc. stock2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Codexis Inc (CDXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):